Special Issue

Radiopharmaceuticals for PET Imaging 2021

Message from the Guest Editors

Following the success of the first issue on "Radiopharmaceuticals for PET Imaging" and the strong research activity in the field, we propose here a second issue gathering very recent advances on radiopharmaceuticals design, starting with the production of innovative radioisotopes for diagnosis or therapy. New synthetic strategies are also being developed, including radiosynthesis, the development of new chelators and nanoparticles for PET imaging, as well as new conjugation strategies. Recent trends in biotargeting also contribute to the success of PET imaging. Emphasis of this issue will also be placed on multimodal probes, and theranostic agents and their preclinical and clinical applications, including neuroimaging, will also be encouraged. You are cordially invited to contribute to this Special Issue on "Radiopharmaceuticals for PET Imaging II" with original articles, perspective papers, and short communications to highlight and review current developments in this field.

Guest Editors

Dr. Aline Nonat

Equipe de Synthèse pour l'Analyse (SynPA), Institut Pluridisciplinaire Hubert Curien, Université de Strasbourg, Strasbourg, France

Dr. Ali Ouadi

Groupe Imagerie Moléculaire, Institut Pluridisciplinaire Hubert Curien, Université de Strasbourg, Strasbourg, France

Deadline for manuscript submissions

closed (31 December 2021)



Molecules

an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.6 Indexed in PubMed



mdpi.com/si/56702

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

mdpi.com/journal/molecules





Molecules

an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.6 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).

